Dose Finding Study to Evaluate Safety, Tolerability and Immunogenicity of an Inactiviated Adjuvanted Sars-Cov-2 Virus Vaccine Candidate Against Covid-19 in Healthy Adults
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT04671017 |
Recruitment Status :
Active, not recruiting
First Posted : December 17, 2020
Last Update Posted : March 9, 2021
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Sars-Cov-2 Virus Infection | Biological: VLA2001 | Phase 1 Phase 2 |
The multicenter, dose finding Phase 1/2 study starts off with an open-label, dose-escalation part, thereafter, during the double-blind part of study, participants will be randomized 1:1:1 to receive the low, medium or high dose of the vaccine (VLA2001). All participants will received a total of two vaccinations intramuscularly, on day 1 and day 22.
The first 5 participants in each dose group will receive VLA2001 open label, starting with the low dose of VLA2001. If no safety concerns are identified, the next 5 subjects will receive the medium dose of the vaccine. Again, if no safety issues are identified, 5 participants will be vaccinated with the high dose vaccine. A Data Safety and Monitoring Board (DSMB) will review accrued safety data before randomization of the remaining 135 subjects across all sites will be initiated.
All study participants will be followed up for safety and immunogenicity up to approximately 6 months after receiving their second vaccination.
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 153 participants |
Allocation: | Randomized |
Intervention Model: | Sequential Assignment |
Intervention Model Description: |
|
Masking: | Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) |
Masking Description: |
|
Primary Purpose: | Prevention |
Official Title: | A Phase I/II Randomized, Two Parts, Dose-Finding Study To Evaluate The Safety, Tolerability and Immunogenicity Of An Inactivated, Adjuvanted Sars-Cov-2 Virus Vaccine Candidate (VLA2001), Against Covid-19 In Healthy Subjects |
Actual Study Start Date : | December 16, 2020 |
Actual Primary Completion Date : | February 26, 2021 |
Estimated Study Completion Date : | August 28, 2021 |
Arm | Intervention/treatment |
---|---|
Experimental: Low Dose: VLA2001 |
Biological: VLA2001
whole virus inactivated SARS-CoV-2 vaccine adjuvanted with cytosine phosphor-guanine (CpG) 1018 in combination with aluminium hydroxide |
Experimental: Medium Dose: VLA2001 |
Biological: VLA2001
whole virus inactivated SARS-CoV-2 vaccine adjuvanted with cytosine phosphor-guanine (CpG) 1018 in combination with aluminium hydroxide |
Experimental: High Dose: VLA2001 |
Biological: VLA2001
whole virus inactivated SARS-CoV-2 vaccine adjuvanted with cytosine phosphor-guanine (CpG) 1018 in combination with aluminium hydroxide |
- Frequency and severity of solicited AEs (local and systemic reactions) within 7 days after any vaccination [ Time Frame: until Day 29 ]
- Geometric mean titre (GMT) for neutralizing antibodies against SARS-CoV-2 [ Time Frame: Day 36 ]
- Frequency and severity of any unsolicited AE [ Time Frame: until Day 36 ]
- Frequency and severity of any vaccine-related AE [ Time Frame: until Day 36 ]
- Frequency and severity of any AE [ Time Frame: until Day 208 ]
- Frequency and severity of any vaccine-related AE [ Time Frame: until Day 208 ]
- Frequency and severity of any SAE [ Time Frame: until Day 36 ]
- Frequency and severity of any AESI [ Time Frame: until Day 36 ]
- Frequency and severity of any SAE [ Time Frame: until Day 208 ]
- Frequency and severity of an AESI [ Time Frame: until Day 208 ]
- Immune response as measured by neutralizing antibody titres against SARS-CoV-2 [ Time Frame: until Day 208 ]
- Proportion of subjects with seroconversion in terms of neutralizing antibodies [ Time Frame: until Day 208 ]
- Fold increase of SARS-CoV-2 neutralizing antibody titres compared with baseline [ Time Frame: until Day 208 ]
- GMTs for IgG antibodies against SARS-CoV-2 [ Time Frame: until Day 208 ]
- Proportion of subjects with seroconversion in terms of IgG antibodies against SARS-CoV-2 in subjects negative for SARS-CoV-2 at screening [ Time Frame: until Day 208 ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 55 Years (Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria - Subjects who meet ALL of the following criteria are eligible for the study:
- Subject is 18 to 55 years of age
- Subject who has a smart phone and is willing and able to install and use the eDiary.
- Subject has an understanding of the study and its procedures, agrees to its provisions, and voluntarily gives written informed consent prior to any study-related procedures.
- Subject is generally healthy as determined by the Investigator
- Subject has a Body Mass Index (BMI) of 18.0-30.0 kg/m2
-
If subject is of childbearing potential:
- Subject has practiced an adequate method of contraception during the 30 days before screening (Visit 0).
- Subject has a negative serum or urine pregnancy test at screening (Visit 0) or Visit 1, respectively.
- Subject agrees to employ adequate birth control measures up to Day 106 (Visit 5).
Exclusion criteria - Subjects who meet ANY of the following criteria are NOT eligible for this study:
- Clinically significant infection or other acute illness, including fever ≥ 38°C within 24 hours prior to the planned study vaccination.
- History of laboratory-confirmed SARS-CoV-2 infection.
- Subject had close contact to persons with confirmed SARS-CoV-2 infection within 30 days prior to screening (Visit 0).
- Subject has participated in a clinical study involving an investigational SARS-CoV-2 vaccine.
- Subject has an acute or recent infection not due to SARS-CoV-2
- Subject has a history of SARS-CoV-1 or MERS infection (self-reported)
- Subject tests positive for human immunodeficiency virus (HIV), hepatitis B surface antigen (HBsAg) or hepatitis C virus (HCV).
- Subject has received any vaccine within 30 days prior Visit 1 other than the study intervention, with the exception of the seasonal influenza vaccination.
- Subject has abnormal findings in any required study investigations (including medical history, physical examination, and clinical laboratory) considered clinically relevant by the Investigator.
- Subjects with either medical history of or present acute or progressive, unstable or uncontrolled clinical conditions that pose a risk for participation or completion of the study, based on Investigator's clinical judgement.
- Subjects with underlying diseases with a high risk of developing severe COVID-19 symptoms if infected
- Subject has a history of malignancy in the past 5 years other than squamous cell or basal cell skin cancer. If there has been surgical excision or treatment more than 5 years ago that is considered to have achieved a cure, the subject may be enrolled. A history of hematologic malignancy is a permanent exclusion. Subjects with a history of skin cancer must not be vaccinated at the previous tumour site.
- Subject has a known or suspected defect of the immune system, such as subjects with congenital or acquired immune deficiency
- Subject received immuno-suppressive therapy within 4 weeks prior to Visit 1 or receipt of immunosuppressive therapy is expected during the study.
- Subject has a history of any vaccine related contraindicating event
- Subject presents with clinical conditions representing a contraindication to intramuscular vaccination and blood draws.
- Subject is pregnant, has plans to become pregnant up to Day 106 of the study or lactating at the time of enrolment.
- Subject has donated blood, blood fractions or plasma within 4 weeks prior to Visit 1 or received blood-derived products (e.g. plasma) within 12 weeks prior to Visit 1 in this study or plans to donate blood or use blood products during the study.
- Subject with clinically significant bleeding disorder (e.g. factor deficiency, coagulopathy or platelet disorder) or prior history of significant bleeding or bruising following IM injections or venepuncture.
- Subject has a rash, dermatological condition or tattoos that would, in the opinion of the Investigator, interfere with injection site reaction rating.
- Subject has a known or suspected problem with alcohol or drug abuse as determined by the Investigator.
- Subject has any condition that, in the opinion of the Investigator, may compromise the subject's well-being, might interfere with evaluation of study endpoints, or would limit the subject's ability to complete the study.
- Subject is committed to an institution (by virtue of an order issued either by the judicial or the administrative authorities).
- Subject has participated in another clinical study involving an investigational medicinal product (IMP) or device within 4 weeks prior to Visit 0 (screening) or is scheduled to participate in another clinical study involving an IMP, or device during the course of this study.
- Subject is a member of the team conducting the study or in a dependent relationship with one of the study team members.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04671017
United Kingdom | |
Queen Elizabeth Hospital | |
Birmingham, United Kingdom, B15 2TH | |
University Hospital Bristol and Weston NHS Foundation Trust | |
Bristol, United Kingdom, BS1 3NU | |
Newcastle University Medical School | |
Newcastle, United Kingdom, NE7 7DN | |
Southampton NIHR Clinical Research Facility | |
Southampton, United Kingdom, SO16 6YD |
Study Chair: | Valneva Clinical Development | Valneva Austria GmbH |
Responsible Party: | Valneva Austria GmbH |
ClinicalTrials.gov Identifier: | NCT04671017 |
Other Study ID Numbers: |
VLA2001-201 |
First Posted: | December 17, 2020 Key Record Dates |
Last Update Posted: | March 9, 2021 |
Last Verified: | March 2021 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | Undecided |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
VLA2001 Sars-Cov-2 Virus Infection Covid-19 inactivated-adjuvanted Sars-Cov-2 virus vaccine |
Virus Diseases |